EMAIL THIS PAGE TO A FRIEND

European respiratory review : an official journal of the European Respiratory Society

Antifibrotic activities of pirfenidone in animal models.


PMID 21632796

Abstract

Pirfenidone is an orally active small molecule that has recently been evaluated in large clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the uncontrolled deposition of extracellular matrix leads to progressive loss of lung function. This review describes the activity of pirfenidone in several well-characterised animal models of fibrosis in the lung, liver, heart and kidney. In these studies, treatment-related reductions in fibrosis are associated with modulation of cytokines and growth factors, with the most commonly reported effect being reduction of transforming growth factor-β. The consistent antifibrotic activity of pirfenidone in a broad array of animal models provides a strong preclinical rationale for the clinical characterisation of pirfenidone in pulmonary fibrosis and, potentially, other conditions with a significant fibrotic component.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P2116
Pirfenidone, ≥97% (HPLC)
C12H11NO